Head-to-head evidence
Cemsidomide vs ICP-490
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Cemsidomide
Developed by C4 Therapeutics, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07280013 (registry estimate)
ICP-490
Developed by Beijing InnoCare Pharma Tech Co.
NCT05719701 · Phase 1/2 · status unknown
This is an unblinded, non-randomized dose-finding study with no control arm, and no results have been posted yet, so it cannot currently demonstrate a controlled treatment effect.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · ICP-490's landscape